Showing results (131-140 of 180) with videos related to

Sort By:
Pageof 18
Blood Advances|March 3, 2023
Cytokine receptor IL27RA is an NF-κB-responsive gene involved in CD38 upregulation in multiple myelomaRebecca J Brownlie, Ruth Kennedy, Erica B Wilson, et al.
Hemasphere|August 29, 2025
Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma NetworkGrigoris Gerotziafas, Despina Fotiou, Inger Nijhof, et al.
BMJ Open|June 2, 2022
<i>F</i>railty-adjusted therapy <i>i</i>n <i>T</i>ransplant <i>N</i>on-<i>E</i>ligible patient<i>s</i> with newly diagno<i>s</i>ed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trialAmy Beth Coulson, Kara-Louise Royle, Charlotte Pawlyn, et al.
Leukemia|December 2, 2020
Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trialJames Croft, Sidra Ellis, Amy L Sherborne, et al.
British Journal of Haematology|July 18, 2015
Optimizing the management of patients with spinal myeloma diseaseSean Molloy, Maggie Lai, Guy Pratt, et al.
The Lancet. Oncology|December 19, 2018
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trialGraham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
British Journal of Haematology|March 29, 2014
Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study resultsGraham H Jackson, Gareth J Morgan, Faith E Davies, et al.
Nature Communications|April 24, 2015
APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myelomaBrian A Walker, Christopher P Wardell, Alex Murison, et al.
Annals of Hematology|May 10, 2021
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the USFaith Davies, Robert Rifkin, Caitlin Costello, et al.
European Journal of Haematology|May 16, 2017
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysisPhilippe Moreau, Meletios A Dimopoulos, Paul G Richardson, et al.
Pageof 18